Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22316960 | 1.00 | APLNR (0.31) | APLNRALDH1A1LMNA | |
| SCHEMBL15875664 | 0.76 | HCAR2 (0.32) | ALDH1A1 | |
| SCHEMBL24083357 | 0.72 | — | — | |
| SCHEMBL22315715 | 0.71 | HRH3 (0.32) | LMNA | |
| SCHEMBL24083358 | 0.69 | — | — | |
| SCHEMBL2080034 | 0.69 | CYP2D6 (0.40) | APLNRALDH1A1 | |
| SCHEMBL4537683 | 0.66 | CYP2D6 (0.35) | APLNR | |
| SCHEMBL19487728 | 0.64 | — | — | |
| SCHEMBL22315709 | 0.63 | CYP2D6 (0.33) | APLNR | |
| SCHEMBL13359076 | 0.63 | HDAC3 (0.36) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637470-B2 | Salts of nitrogen-containing heterocyclic compound, and solid forms of salts, pharmaceutical composition and use thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12221449-B2 | Pyrrolopyrimidine derivative and use thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-11 | — | — | US | disclosed |
| EP-3919498-B3 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN) | 2024-09-04 | — | — | EP | disclosed |
| EP-3919498-B1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20230312582-A1 | Salts Of Nitrogen-Containing Heterocyclic Compound, And Solid Forms Of Salts, Pharmaceutical Composition And Use Thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312582-A1 | Salts Of Nitrogen-Containing Heterocyclic Compound, And Solid Forms Of Salts, Pharmaceutical Composition And Use Thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312582-A1 | Salts Of Nitrogen-Containing Heterocyclic Compound, And Solid Forms Of Salts, Pharmaceutical Composition And Use Thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4190783-A1 | SALTS OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND SOLID FORMS OF SALTS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190783-A1 | SALTS OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND SOLID FORMS OF SALTS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-06-07 | — | — | EP | disclosed |
| CN-111518101-B | Pyrrolopyrimidine derivatives and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220064172-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-03-03 | — | — | US | disclosed |
| WO-2020156459-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064172-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | ATXN2, ATXN2L, ATXN10 | APLNR 2960/4885ALDH1A1 2720/4885LMNA 1627/4885 |
| US-12221449-B2 | Pyrrolopyrimidine derivative and use thereof | ATXN2, ATXN2L, ATXN10 | APLNR 2960/4885ALDH1A1 2720/4885LMNA 1627/4885 |
| US-20230312582-A1 | Salts Of Nitrogen-Containing Heterocyclic Compound, And Solid Forms Of Salts, Pharmaceutical Composition And Use Thereof | ATXN10, ATXN2, ATXN2L | APLNR 4240/4885ALDH1A1 3782/4885LMNA 1953/4885 |
| US-12637470-B2 | Salts of nitrogen-containing heterocyclic compound, and solid forms of salts, pharmaceutical composition and use thereof | ATXN10, ATXN2, ATXN2L | APLNR 3989/4885ALDH1A1 2636/4885LMNA 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.